Picture of Mesa Laboratories logo

MLAB — Mesa Laboratories News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Mesa Labs Q1 revenue up 2.4%, operating income down 45%

Overview

Mesa Labs fiscal Q1 revenue grows 2.4% yr/yr, driven by strong SDC growth

Operating income declines 45.1% due to FX impacts and stock-based compensation

Co expects improved AOI as percentage of revenues in fiscal Q2

Outlook

Company expects 2Q26 revenue boost from delayed BPD orders

Mesa sees AOI percentage improving in 2Q26

Company aims to reduce past-due backlog in FY26

Mesa expects BPD gross profit to improve as mix normalizes

Result Drivers

SDC GROWTH - Sterilization and Disinfection Control division saw 7.5% core organic revenue growth, driven by strong commercial execution and reduced backlog

BPD DELAYS - Biopharmaceutical Development division faced a 7.0% decline in core organic revenues due to order timing delays and shipping issues

CG CHINA CONTRACTION - Clinical Genomics division experienced a 69% revenue contraction in China, attributed to macroeconomic and regulatory challenges

Key Details

MetricBeat/MissActualConsensus Estimate
Q1 EPS$0.85
Q1 Net Income$4.74 mln
Q1 Basic EPS$0.87
Q1 Gross Profit$36.94 mln
Q1 Operating Expenses$33.88 mln
Q1 Operating Income$3.06 mln
Press Release: ID:nGNX2DJpmN (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Mesa Laboratories

See all news